Lisa H Buckley1, Rui Xiao2, Marissa J Perman3, Andrew B Grossman4, Pamela F Weiss3. 1. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, and Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee. 2. Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia. 3. Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 4. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: To estimate the incidence rate (IR) of psoriasis in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic noninfectious osteomyelitis (CNO) with tumor necrosis factor inhibitor (TNFi) exposure as compared to children without TNFi exposure and to the general pediatric population. METHODS: This was a single-center retrospective cohort study of children with IBD, JIA, or CNO from 2008 to 2018. TNFi exposure was defined as a prescription for adalimumab, etanercept, infliximab, certolizumab, or golimumab, and the primary outcome was incident psoriasis. IRs and standardized incidence ratios (SIRs) were calculated. Cox proportional hazards models were used to assess the association of psoriasis with TNFi exposure and other risk factors. RESULTS: Of the 4,111 children who met inclusion criteria, 1,614 (39%) had TNFi exposure and 2,497 (61%) did not, with 4,705 and 6,604 person-years of follow-up, respectively. There were 58 cases (IR 12.3 per 1,000 person-years) and 25 cases (IR 3.8 per 1,000 person-years) of psoriasis in children with and without TNFi exposure, respectively. The SIR was 18 (95% confidence interval [95% CI] 15-22) overall, 30 (95% CI 23-39) for children with TNFi exposure, and 9.3 (95% CI 6.3-14) for children without TNFi exposure. The hazard ratio of psoriasis comparing TNFi exposure to no TNFi exposure was 3.84 (95% CI 2.28-6.47; P < 0.001). CONCLUSION: Children with IBD, JIA, and CNO had an increased rate of psoriasis compared to the general pediatric population, with the highest rate in those with TNFi exposure.
OBJECTIVE: To estimate the incidence rate (IR) of psoriasis in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic noninfectious osteomyelitis (CNO) with tumor necrosis factor inhibitor (TNFi) exposure as compared to children without TNFi exposure and to the general pediatric population. METHODS: This was a single-center retrospective cohort study of children with IBD, JIA, or CNO from 2008 to 2018. TNFi exposure was defined as a prescription for adalimumab, etanercept, infliximab, certolizumab, or golimumab, and the primary outcome was incident psoriasis. IRs and standardized incidence ratios (SIRs) were calculated. Cox proportional hazards models were used to assess the association of psoriasis with TNFi exposure and other risk factors. RESULTS: Of the 4,111 children who met inclusion criteria, 1,614 (39%) had TNFi exposure and 2,497 (61%) did not, with 4,705 and 6,604 person-years of follow-up, respectively. There were 58 cases (IR 12.3 per 1,000 person-years) and 25 cases (IR 3.8 per 1,000 person-years) of psoriasis in children with and without TNFi exposure, respectively. The SIR was 18 (95% confidence interval [95% CI] 15-22) overall, 30 (95% CI 23-39) for children with TNFi exposure, and 9.3 (95% CI 6.3-14) for children without TNFi exposure. The hazard ratio of psoriasis comparing TNFi exposure to no TNFi exposure was 3.84 (95% CI 2.28-6.47; P < 0.001). CONCLUSION: Children with IBD, JIA, and CNO had an increased rate of psoriasis compared to the general pediatric population, with the highest rate in those with TNFi exposure.
Authors: Megha M Tollefson; Cynthia S Crowson; Marian T McEvoy; Hilal Maradit Kremers Journal: J Am Acad Dermatol Date: 2009-12-05 Impact factor: 11.527
Authors: E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald Journal: Gastroenterology Date: 1994-06 Impact factor: 22.682
Authors: Iván Guerra; Tamara Pérez-Jeldres; Marisa Iborra; Alicia Algaba; David Monfort; Xavier Calvet; María Chaparro; Miriam Mañosa; Esther Hinojosa; Miguel Minguez; Jone Ortiz de Zarate; Lucía Márquez; Vanessa Prieto; Valle García-Sánchez; Jordi Guardiola; G Esther Rodriguez; María Dolores Martín-Arranz; Iván García-Tercero; Beatriz Sicilia; Ángeles Masedo; Rufo Lorente; Montserrat Rivero; Luis Fernández-Salazar; Ana Gutiérrez; Manuel Van Domselaar; Antonio López-SanRomán; Yolanda Ber; Marifé García-Sepulcre; Laura Ramos; Fernando Bermejo; Javier P Gisbert Journal: Inflamm Bowel Dis Date: 2016-04 Impact factor: 5.325